Payden & Rygel Increases Stock Position in Pfizer Inc. $PFE

Payden & Rygel increased its position in shares of Pfizer Inc. (NYSE:PFE) by 53,868.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 205,080 shares of the biopharmaceutical company’s stock after buying an additional 204,700 shares during the period. Payden & Rygel’s holdings in Pfizer were worth $5,106,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Stronghold Wealth Management L.L.C. acquired a new stake in Pfizer during the 4th quarter valued at approximately $231,000. Entrust Financial LLC acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $65,000. Pathway Financial Advisers LLC boosted its stake in shares of Pfizer by 0.9% during the 4th quarter. Pathway Financial Advisers LLC now owns 46,380 shares of the biopharmaceutical company’s stock valued at $1,155,000 after buying an additional 403 shares during the last quarter. Blume Capital Management Inc. grew its position in shares of Pfizer by 0.7% during the fourth quarter. Blume Capital Management Inc. now owns 228,305 shares of the biopharmaceutical company’s stock worth $5,685,000 after buying an additional 1,684 shares in the last quarter. Finally, Integrated Investment Consultants LLC grew its position in shares of Pfizer by 102.8% during the fourth quarter. Integrated Investment Consultants LLC now owns 51,012 shares of the biopharmaceutical company’s stock worth $1,270,000 after buying an additional 25,861 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of several recent analyst reports. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Citigroup boosted their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Wednesday, February 4th. Wolfe Research reiterated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research note on Thursday. Finally, Royal Bank Of Canada restated an “underperform” rating and set a $25.00 price objective on shares of Pfizer in a research note on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $28.84.

Pfizer Price Performance

Shares of PFE opened at $25.31 on Tuesday. Pfizer Inc. has a 12 month low of $22.64 and a 12 month high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The stock has a fifty day moving average price of $26.96 and a 200 day moving average price of $26.20. The company has a market cap of $144.22 billion, a P/E ratio of 19.32 and a beta of 0.35.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same period last year, the business posted $0.92 earnings per share. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s payout ratio is presently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.